Imperial College London
Alternate

ProfessorMartaBoffito

Faculty of Medicine, Department of Infectious Disease

Professor of Practice
 
 
 
//

Contact

 

+44 (0)20 3315 6148m.boffito

 
 
//

Location

 

St StephensChelsea and Westminster Campus

//

Summary

 

Publications

Citation

BibTex format

@article{De:2009:10.2147/vhrm.s5206,
author = {De, Lorenzo F and Boffito, M and Collot-Teixeira, S and Gazzard, B and McGregor, JL and Shotliff, K and Xiao, H},
doi = {10.2147/vhrm.s5206},
journal = {Vasc Health Risk Manag},
pages = {287--300},
title = {Prevention of atherosclerosis in patients living with HIV.},
url = {http://dx.doi.org/10.2147/vhrm.s5206},
volume = {5},
year = {2009}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - UNLABELLED: INVESTIGATIONAL PRODUCT: Rosuvastatin (Crestor; Astra Zeneca). ACTIVE INGREDIENTS: Rosuvastatin (5 mg). STUDY TITLE: Prevention of Atherosclerosis in Patients Living with HIV. PHASE OF STUDY: Phase III. AIMS: PRIMARY AIM: To assess whether rosuvastatin therapy could slow the progression of the carotid intima-media thickness (C-IMT; as measured by the change in the mean IMT of the near and far walls of the distal common carotid arteries) over 2 years in HIV-infected patients (HIV-IP). SECONDARY AIMS: To assess whether rosuvastatin therapy could reduce highly sensitive C reactive protein (hs-CRP) inflammatory marker that is increased in HIV-IP.To assess the effect of rosuvastatin therapy on serum lipid levels (total cholesterol [TC], low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol and triglycerides [TG]) and apolipoproteins (APO A1, APO B and APO B/A1).To assess the safety of rosuvastatin in HIV-IP through the evaluation of clinical laboratory analyses (liver function tests and creatine kinase) and adverse events (AEs). STUDY DESIGN: Two-year randomized, double-blind, placebo-controlled, parallel group study. PLANNED SAMPLE SIZE: 320 HIV-IP. SUMMARY OF ELIGIBILITY CRITERIA: HIV-IP who are aged between 30 and 60 years, with a CD4 count. greater than 200 cells/mm(3). Patients must be stable on combination antiretroviral therapy (cART) for at least 12 months and have a 10-year CVD risk of less than 20% (using the Framingham risk score). NUMBER OF STUDY CENTERS: One. DURATION OF TREATMENT: Two years (5 mg rosuvastatin or placebo once daily). DOSE AND ROUTE OF ADMINISTRATION: Oral rosuvastatin (5 mg) once daily. The incidence of cardiovascular disease (CVD) in HIV-IP is at least three times higher than in the general population and further increases each year with combination anti-retroviral therapy (cART). The carotid atherosclerosis progression rate is 10 times higher in HIV-IP than in uninfected individuals. The aim of t
AU  - De,Lorenzo F
AU  - Boffito,M
AU  - Collot-Teixeira,S
AU  - Gazzard,B
AU  - McGregor,JL
AU  - Shotliff,K
AU  - Xiao,H
DO  - 10.2147/vhrm.s5206
EP  - 300
PY  - 2009///
SP  - 287
TI  - Prevention of atherosclerosis in patients living with HIV.
T2  - Vasc Health Risk Manag
UR  - http://dx.doi.org/10.2147/vhrm.s5206
UR  - https://www.ncbi.nlm.nih.gov/pubmed/19436663
VL  - 5
ER  -
Download